VILINBIO Stock Overview
Engages in the manufacture and sale of pharmaceutical products in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Vilin Bio Med Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹20.30 |
| 52 Week High | ₹30.45 |
| 52 Week Low | ₹15.40 |
| Beta | 0 |
| 11 Month Change | -16.80% |
| 3 Month Change | 9.73% |
| 1 Year Change | -4.47% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -28.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| VILINBIO | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 3.6% | -0.2% | 0.3% |
| 1Y | -4.5% | 40.5% | 27.3% |
Return vs Industry: VILINBIO underperformed the Indian Pharmaceuticals industry which returned 40.5% over the past year.
Return vs Market: VILINBIO underperformed the Indian Market which returned 27.3% over the past year.
Price Volatility
| VILINBIO volatility | |
|---|---|
| VILINBIO Average Weekly Movement | 15.7% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: VILINBIO's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: VILINBIO's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | Anuj Bajpai | www.vilinbiomed.co.in |
Vilin Bio Med Limited engages in the manufacture and sale of pharmaceutical products in India. The company provides cardiovascular, musculo-skeletal, antibiotic, central nervous system, alimentary system, genito-urinary tract, respiratory system and anti-allergic, anti- diabetic, liquid orals, and miscellaneous drugs, as well as multi-vitamins, minerals, and amino acids supplements. It offers its products in the form of oral liquids, dry syrups, sachets, external preparations, beta and non beta lactam tablets and capsules, and nutritional food supplements.
Vilin Bio Med Limited Fundamentals Summary
| VILINBIO fundamental statistics | |
|---|---|
| Market cap | ₹283.19m |
| Earnings (TTM) | -₹4.82m |
| Revenue (TTM) | ₹130.85m |
2.2x
P/S Ratio-58.7x
P/E RatioIs VILINBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VILINBIO income statement (TTM) | |
|---|---|
| Revenue | ₹130.85m |
| Cost of Revenue | ₹119.78m |
| Gross Profit | ₹11.07m |
| Other Expenses | ₹15.89m |
| Earnings | -₹4.82m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.35 |
| Gross Margin | 8.46% |
| Net Profit Margin | -3.69% |
| Debt/Equity Ratio | 32.0% |
How did VILINBIO perform over the long term?
See historical performance and comparison